Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field AIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and...
Published in: | European Heart Journal |
---|---|
Main Authors: | , , , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Oxford University Press
2010
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/93623 https://doi.org/10.1053/euhj.1998.1191 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/93623 |
---|---|
record_format |
openpolar |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/93623 2023-05-15T16:50:57+02:00 Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) Faergeman, O Kjekshus, J Cook, T Pyörälä, K Wilhelmsen, L Thorgeirsson, G Pedersen, T R Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus, Denmark. 2010-03-04 http://hdl.handle.net/2336/93623 https://doi.org/10.1053/euhj.1998.1191 en eng Oxford University Press http://dx.doi.org/10.1053/euhj.1998.1191 Eur. Heart J. 1998, 19(10):1531-7 0195-668X 9820992 doi:10.1053/euhj.1998.1191 http://hdl.handle.net/2336/93623 European heart journal Angiotensin-Converting Enzyme Inhibitors Anticholesteremic Agents Aspirin Calcium Channel Blockers Cause of Death Coronary Disease Female Finland Follow-Up Studies Humans Iceland Male Middle Aged Myocardial Revascularization Prognosis Scandinavia Simvastatin Survival Rate Warfarin Article 2010 ftlandspitaliuni https://doi.org/10.1053/euhj.1998.1191 2022-05-29T08:21:30Z To access publisher full text version of this article. Please click on the hyperlink in Additional Links field AIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo. Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy. There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries. Surgical and medical therapy varied importantly between countries. CONCLUSIONS: Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking. They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease. Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive European Heart Journal 19 10 1531 1537 |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
Angiotensin-Converting Enzyme Inhibitors Anticholesteremic Agents Aspirin Calcium Channel Blockers Cause of Death Coronary Disease Female Finland Follow-Up Studies Humans Iceland Male Middle Aged Myocardial Revascularization Prognosis Scandinavia Simvastatin Survival Rate Warfarin |
spellingShingle |
Angiotensin-Converting Enzyme Inhibitors Anticholesteremic Agents Aspirin Calcium Channel Blockers Cause of Death Coronary Disease Female Finland Follow-Up Studies Humans Iceland Male Middle Aged Myocardial Revascularization Prognosis Scandinavia Simvastatin Survival Rate Warfarin Faergeman, O Kjekshus, J Cook, T Pyörälä, K Wilhelmsen, L Thorgeirsson, G Pedersen, T R Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) |
topic_facet |
Angiotensin-Converting Enzyme Inhibitors Anticholesteremic Agents Aspirin Calcium Channel Blockers Cause of Death Coronary Disease Female Finland Follow-Up Studies Humans Iceland Male Middle Aged Myocardial Revascularization Prognosis Scandinavia Simvastatin Survival Rate Warfarin |
description |
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field AIM: To assess differences in treatment of ischaemic heart disease in the Scandinavian countries. METHODS AND RESULTS: The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo. Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy. There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries. Surgical and medical therapy varied importantly between countries. CONCLUSIONS: Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking. They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease. |
author2 |
Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus, Denmark. |
format |
Article in Journal/Newspaper |
author |
Faergeman, O Kjekshus, J Cook, T Pyörälä, K Wilhelmsen, L Thorgeirsson, G Pedersen, T R |
author_facet |
Faergeman, O Kjekshus, J Cook, T Pyörälä, K Wilhelmsen, L Thorgeirsson, G Pedersen, T R |
author_sort |
Faergeman, O |
title |
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) |
title_short |
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) |
title_full |
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) |
title_fullStr |
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) |
title_full_unstemmed |
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) |
title_sort |
differences in the treatment of coronary heart disease between countries as revealed in the scandinavian simvastatin survival study (4s) |
publisher |
Oxford University Press |
publishDate |
2010 |
url |
http://hdl.handle.net/2336/93623 https://doi.org/10.1053/euhj.1998.1191 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://dx.doi.org/10.1053/euhj.1998.1191 Eur. Heart J. 1998, 19(10):1531-7 0195-668X 9820992 doi:10.1053/euhj.1998.1191 http://hdl.handle.net/2336/93623 European heart journal |
op_doi |
https://doi.org/10.1053/euhj.1998.1191 |
container_title |
European Heart Journal |
container_volume |
19 |
container_issue |
10 |
container_start_page |
1531 |
op_container_end_page |
1537 |
_version_ |
1766041067871797248 |